The novel stem-cell derived retinal organoid provided a new understanding of the disease by showing that damage to retinal pigment epithelium cells is enough to cause neurodegeneration of photoreceptors.
Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability.
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then.
First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss.
Scientists showed that a trio of medications successfully cleared the virus in a rhesus macaque infant model. Clinical testing in human infants could move quickly.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.